Scientific & technology overview
Making complex solutions simple.
Medicine has a delivery problem, not a molecule problem.
One absorption platform. Three delivery architectures. The molecules the market already wants — without the needle, without the cold chain, and with the intellectual property on how.
Section 01
The needle is a delivery failure, not a clinical necessity.
Peptide and metabolic medicines are injected for two mechanical reasons, not commercial ones. First, the digestive tract is built to break proteins apart — a peptide swallowed as a pill is destroyed before it can work. Second, whatever survives is routed through the liver, which strips out most of what remains before it ever reaches the bloodstream. Every serious attempt at an oral peptide has failed on one or both.
Our platform solves both by delivering the molecule before it ever reaches the stomach — absorbed directly into the bloodstream through the highly permeable tissue under the tongue, or through the nasal mucosa, rather than surviving a trip through the gut and the liver.
The molecules themselves are known, characterized and already prescribed. Prism is not making a discovery bet on new chemistry. What we own is the architecture that delivers proven molecules without a needle — at dose precision, stable at room temperature, and protected by a layered IP estate.
Why this is a platform, not a product
The same absorption science underlies every format. A molecule is matched to the architecture its chemistry suits, rather than each new molecule requiring a new invention. That is the structural difference between a delivery platform and a single reformulated asset — and it is what lets one validated science address many needs.
One science, three architectures
Matched to the molecule, never the other way around.
Orally Dissolving Tablet
Route of absorption
Sublingual / buccal
What it bypasses
Digestive breakdown and liver first-pass
Oral Thin Film
Route of absorption
Sublingual primary, buccal per molecule
What it bypasses
Digestive breakdown and liver first-pass
Intranasal
Route of absorption
Nasal mucosa, metered dose
What it bypasses
Digestive breakdown and liver first-pass
Section 02
The delivery system, layer by layer.
The finished product is a stamp-sized strip or a small tablet placed under the tongue. It looks unremarkable. Its value is entirely in what is engineered into layers thinner than paper — each one solving a specific reason these medicines have stayed on needles.
A one-way street, not a lozenge
Ordinary dissolving strips release drug in every direction — most of it is swallowed and meets the same fate as a pill. Our architecture carries an occlusive backing layer, so the peptide can travel in one direction only: into the tissue and the bloodstream, not into the saliva. Characterized work indicates the design drives several times as much drug into the tissue as is lost to the mouth.
It grips like a micro-bandage and buys time
Absorption needs time, and the floor of the mouth is where saliva flows fastest — most oral formats are washed away before the molecule can cross. A mucoadhesive polymer layer anchors the dose against that flow for the full absorption window, and quietly disarms the surface enzymes that would otherwise break the peptide apart on contact.
The molecule rides inside a protective carrier
The fragile active is ion-paired to neutralise its electrical charge, then wrapped in a microscopic, deformable lipid carrier. Three jobs at once: it presents the molecule as something the tissue will admit, shields it in transit, and — because the carrier flexes rather than holds rigid — lets it pass between cells that would otherwise block anything that size.
An excipient matrix tuned per molecule
Permeation enhancers, buffers and matrix chemistry are optimised molecule by molecule rather than reused as a house recipe. Each layer is characterised independently, then optimised as a stack — which is why the platform extends to new actives instead of requiring a new invention each time.
Five defenses, one dose
Most delivery companies solve one of five. We answer all five at once.
- 01It gets digested before it works
- 02It cannot cross the mucosal lining
- 03It is chemically fragile in transit
- 04The liver strips out what survives
- 05The regimen is too difficult to stay on
The hardest case
Some molecules are large and permanently charged, with a very short life in the body — effectively unabsorbable by any ordinary oral route. No amount of extra milligrams solves that; the molecule simply never gets in. It is not a dosing problem, it is a delivery problem — and it is precisely the problem the protective-carrier architecture is built for.
What it means for you
Pharmaceutical precision, without the friction.
No needle
A strip or tablet under the tongue instead of a subcutaneous injection. The format is what determines who starts therapy and who stays on it.
No refrigerator
Room-temperature stable, shipped in an envelope. No cold box, no spoilage, no delivery window you have to be home for.
Dose you can trust
Uniform dose per unit, raw material fingerprinted before use, every batch third-party tested. A categorical difference from gray-market powders, not an incremental one.
Tailored to you
A physician intake and a prescription compounded patient by patient at a licensed 503A pharmacy — personalized medicine, delivered in a format built for real life.
Section 03
A full IP system, not a single point of defense.
The moat is deliberately layered, and the layers reinforce one another. Reproducing the result means defeating all of them at once — reading a patent alone does not get anyone there.
Layered patents
Provisional and pending filings covering the platform itself — the directional bilayer, the protective-carrier payload architecture, and the adhesion and permeation methods — drafted to read on every format we make, not only a lead product.
Trade secrets
Process windows, layer chemistry ratios and manufacturing parameters that never appear in a filing. Reading a patent does not reproduce a working film.
Manufacturing control
Quality systems, incoming raw-material identity testing by mass spectrometry, and batch-level release records — so dose uniformity is a specification, not a claim.
Vertical integration
We own the delivery technology, the molecule pipeline, the quality system and the patient relationship. Cherry-picking one molecule out of that system strands the value rather than transferring it.
Section 04
Engineered design, then independent evidence.
Permeation and stability work is run by third-party accredited contract research organisations — independent labs with no stake in the outcome, including human-tissue permeation models that measure how much drug actually crosses.
Compounding happens at a licensed, LegitScript-certified 503A pharmacy, dosed patient by patient against a prescription. Raw peptide identity is confirmed by mass spectrometry before use, and every batch is third-party tested before it ships.
All formulation performance figures are characterized (preclinical) unless otherwise stated. The specifics of our supply chain stay ours.
Launching Fall 2026
The science is built. Be first in line.
Join the list for early access and a pre-launch discount on your first order.